摘要
目的探讨慢性阻塞性肺疾病(COPD)急性加重期及社区获得性肺炎(CAP)患者治疗前后血清及痰液中IL-18的变化及意义。方法采用双抗体夹心ELISA法对45例COPD急性加重期患者治疗前后血清及痰液中IL-18进行检测,同时与15例CAP患者及15例健康人对照。结果COPD急性加重期患者治疗前血清及痰液中IL-18水平明显高于治疗后及健康组,且治疗后水平仍高于健康组。CAP组治疗前血清及痰液中IL-18高于健康组,治疗后水平与健康组比较差异无统计学意义。结论IL-18参与了COPD的发生发展过程,持续升高的IL-18可能是造成COPD患者气道炎症迁延不愈的重要原因。在CAP的急性炎症过程中,短暂升高可能对机体起保护作用。
Objective To investigate the change and significance of IL-18 in serum and sputum between prior-therapy and post-therapy from patients with AECOPD and CAP. Methods IL-18 in the serum and sputum were determined by enzyme-linked immunosorbent assay in 45 patients with AECOPD, 15 patients with CAP, and 15 normal groups were included. Results IL-18 in serum and sputum levels in COPD group were significantly higher than those of control group before and after treatment. High levels of IL-18 were also observed in patients with CAP during prior-therapy and levels significantly decreased after treatment and there were no significant differences compared with control group. Conclusion IL-18 contributes to the development of COPD and continuous high levels of IL-18 may be important factors resulting in chronic airway inflammation. Raised transiently of IL-18 may be helpful for us during CAP course.
出处
《贵州医药》
CAS
2009年第9期784-787,共4页
Guizhou Medical Journal
关键词
慢性阻塞性肺疾病
社区获得性肺炎
白细胞介素-18
气道炎症
Chronic obstructive pulmonary disease Community acquired pneumonia Interleukin-18 Airway inflammation
